DavidGriffithMD

PubMed

• Pharmacodynamics of Minocycline Against Acinetobacter Baumannii in a Rat Pneumonia Model
  David Griffith, MD> ;Antimicrobial Agents and Chemotherapy. 2018 Nov 07
• Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem
  David Griffith, MD> ;Antimicrobial Agents and Chemotherapy.
• Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-lactamase Inhibitor, in Combination with Meropenem.
  Griffith, D. C.,Sabet, M.,Tarazi, Z.,Lomovskaya, O.,Dudley, M. N.> ;Antimicrob. Agents Chemother.. 2018 Nov 07
• Activity of Meropenem-Vaborbactam Against Pseudomonas Aeruginosa and Acinetobacter Baumannii in a Neutropenic Mouse Thigh Infection Model
  David Griffith, MD> ;10.1128/AAC.01665-18. 2018 Oct 17
• Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics Vaborbactam and Meropenem Alone and in Combination Following Single and Multiple Doses in Healthy Adult...
  David Griffith, MD> ;mBio. 2018 Feb 14
• Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.
  Sabet, M.,Tarazi, Z.,Rubio-Aparicio, D.,Nolan, T. G.,Parkinson, J.,Lomovskaya, O.,Dudley, M. N.,Griffith, D. C.> ;Antimicrob. Agents Chemother.. 2017 Nov 15
• Meropenem-Vaborbactam: Single-Dose Pharmacokinetics and Safety in Subjects with Chronic Renal Impairment
  Jeffery S Loutit, David C Griffith> ;mBio. 2018 Jan 10
• Nontuberculous Mycobacterial Disease Therapy: Take It to the Limit One More Time.
  Griffith, D. E.,Aksamit, T. R.> ;Chest. 2016 Dec 13
• Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Β-lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects
  Jeffery S Loutit, David C Griffith> ;mBio. 2016 Aug 17
• Join now to see all